Fibrinopeptide A, human CAS NO.25422-31-5
Fibrinopeptide A, human CAS NO.25422-31-5
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | Fibrinopeptide A, human |
| CAS NO. | 25422-31-5 |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C₆₃H₉₇N₁₉O₂₆ |
| Molecular Weight | 1536.59 g/mol |
| Purity (RP-HPLC) | ≥ 98.0% |
| Solubility | Soluble in water (pH 4.0–7.0) or 0.1 M acetic acid; slightly soluble in DMSO (≤5 mg/mL) |
| Endotoxin | < 1.0 EU/mg |
| Biological Activity | Released from fibrinogen during thrombin-mediated cleavage; regulates fibrin polymerization and blood clotting kinetics. Used to study coagulation disorders, thrombolytic therapy, and fibrin structure-function relationships. |
| Storage Conditions | Store at -20°C in a desiccated, light-protected container; avoid repeated freeze-thaw cycles. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
Fibrinopeptide A is released from fibrinogen during thrombin-catalyzed cleavage (at Arg¹⁶-Gly¹⁷ bond). Its primary actions include:
Initiating Fibrin Polymerization: Removal of Fibrinopeptide A exposes polymerization sites (e.g., Gln¹⁶ and Gly¹⁷) on fibrinogen, enabling lateral aggregation of fibrin monomers into protofibrils.
Regulating Clot Structure: Modulates the density and stability of fibrin clots by influencing protofibril branching and cross-linking.
Biomarker Function: Elevated plasma levels correlate with thrombotic activity, serving as a diagnostic marker for deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC).
2.PRODUCT INDICATIONS
This peptide is widely used in:
Coagulation Research: Studying thrombin-fibrinogen interactions, fibrin assembly dynamics, and clot structure-function relationships.
Diagnostic Development: Developing ELISA kits or immunoassays for detecting hypercoagulable states (e.g., DVT, PE, sepsis-induced DIC).
Drug Screening: Evaluating anticoagulant/antithrombotic agents (e.g., direct thrombin inhibitors, fibrinogen modulators) in preclinical models.
3.CLINICAL EFFICACY OF PRODUCT
Biomarker Utility: Plasma Fibrinopeptide A levels rise 10–100-fold during active thrombosis, enabling early detection of thrombotic events (validated in clinical studies).
Research Applications: In vitro studies confirm its role in accelerating fibrin clot formation (2–3x faster polymerization vs. uncleaved fibrinogen).
Diagnostic Accuracy: ELISA-based assays using this peptide achieve >90% sensitivity/specificity for DVT diagnosis in multicenter trials.
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
May 25, 26
Premium API Oxandrolone Ucinky Manufacturing
Premium API Oxandrolone Ucinky Manufacturing Leading global supplier of high-purity chemical raw materials for pharmaceutical grade Oxandrolone Ucinky, combining precision engineering with industrial scale. 5000 kg Annual Output 120 Countries Served 5 Days Sample Lead Time 99.7 On-Time Delivery Industrial Precision Pure Chemical Synthesis Engineering the future of pharmaceutical intermediates with unmatched stability. Our facility stands as a global leader in the oxandrolone ucinky sector, utilizing CRYOGENIC CRYSTALLIZATION and advanced chromatography to ensure an assay purity exceeding 99.8. We integrate a fully automated closed-loop system that eliminates human error and contamination.
May 22, 26
Clinical Benefits and Applications of Oxandrolone Therapy
Oxandrolone therapy represents a sophisticated intersection of endocrine science and regenerative medicine, primarily utilized to address muscle wasting and metabolic dysfunction. In the global pharmaceutical landscape, this specific approach to androgen therapy is valued for its unique ability to promote protein synthesis while exhibiting a lower androgenic profile compared to traditional steroids, making it a critical tool for patients recovering from severe trauma or chronic illness. From a clinical perspective, understanding the nuances of oxandrolone therapy is essential for optimizing patient outcomes in weight gain and tissue repair.
May 20, 26
Clinical Benefits and Production of Oxandrolone Steroid
The global pharmaceutical landscape has seen a significant rise in the demand for highly specialized anabolic agents, among which the oxandrolone steroid stands out due to its unique chemical profile and therapeutic versatility. As a modified version of dihydrotestosterone, this compound provides a potent means of addressing muscle wasting and metabolic deficits, making it a critical asset in both clinical rehabilitation and advanced physiological research. Understanding the nuances of this synthetic compound is essential for healthcare providers and researchers alike, as it balances efficacy with a relatively lower androgenic profile compared to other steroids.
